Dana-Farber Cancer Institute recently partnered with CancerConnect and Ursula Matulonis, MD, to answer questions about ovarian cancer. Experts in the Susan F. Smith Center for Women’s Cancers offer the latest research and treatment for this type of cancer. Watch one patient’s story. Q: Is taking curcumin recommended to prevent ovarian cancer from returning? Do you have any other suggestions for preventing recurrence?
By Ursula Matulonis, MD After a long period of slow progress, new knowledge about the genetics of ovarian cancer is leading to the development and testing of new therapies. Researchers at the Susan F. Smith Center for Women’s Cancers will soon be launching several phase 3 clinical trials testing drugs known as PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer – tumors that initially responded to platinum-based chemotherapy agents but have shown evidence of regrowth at least six months after treatment. Phase 3 trials test drugs in large numbers of patients to evaluate the drugs’ effectiveness as well as …
When Angelina Jolie underwent a preventative double mastectomy earlier this year, this issue of cancer risk and genetics made front-page headlines. Jolie, who announced the operation in a New York Times op-ed, tested positive for the BRCA1 gene mutation and learned she had an 87 percent risk of developing breast cancer. Jolie’s announcement left many women wanting to know more: What is a gene mutation? Should I undergo genetic testing? What should I do if my tests are positive?
By Maura Perkins I can’t pinpoint when I started to get ovarian cancer symptoms. It was all very subtle and gradual. I was a healthy person. I ran, biked swam, hiked, and went to the gym regularly. A slight pain in my left side, difficulty digesting food, feeling of fullness, and shortness of breath: those were the subtle constellation of symptoms that landed me in my primary care doctor’s office. At the age of 50, I felt like I was going downhill fast.
By Melanie Graham During a child’s cancer therapy and recovery process, insomnia can often be viewed as only a side effect in the scope of treatment-related symptoms. However, there are many physical and psychological implications that develop when a child does not sleep well, says Eric Zhou, PhD, a clinical psychology fellow in Dana-Farber’s David B. Perini, Jr. Quality of Life Clinic. Zhou, who is also a research fellow at Harvard Medical School, has spent the last year studying treatments for insomnia in adolescent and young adult cancer survivors through Dana-Farber’s Swim Across America Fellowship.
More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas. Two decades after the war, a thoracic surgeon named Gustav Lindskog used nitrogen mustard to successfully treat a patient with non-Hodgkin’s lymphoma.
The drug Avastin, when added to initial therapy for glioblastoma, can give patients a few extra months’ reprieve before their brain tumors start growing again, but does it make their quality of life better – or worse? That’s a matter of heated debate for doctors – and confusion for patients – after two large clinical trials reported conflicting results at the annual American Society of Clinical Oncology (ASCO) conference in June. Some experts contend that Avastin lacked sufficient benefit for use as an “upfront” treatment for glioblastomas – the most common and aggressive brain tumors.
By Wendy Chen, MD Dana-Farber Breast Oncology Center Susan F. Smith Center for Women’s Cancers Millions of women in the United States have sought treatment for fertility-related problems over the past 35 years. Because many of these treatments –including fertility drugs and in vitro fertilization (IVF) – use hormones to stimulate ovulation, researchers have explored whether such therapies might increase the risk of breast or ovarian cancer.